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The gut microbiota and cardiovascular health
benefits: A focus on wholegrain oats
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Abstract Existing scientific data suggest that a high intake of wholegrain foods contributes
to improved gut health and a reduced risk of cardiovascular disease. Wholegrain
oats are rich in dietary fibre and an important source of many bioactive
components, including minerals, vitamins and phenolic compounds. The oat
b-glucans have been reported to lower low-density lipoprotein cholesterol
through their ability to increase the viscosity of intestinal chime, change the gut
microbiota composition and increase the production of short-chain fatty acids,
which may contribute to the inhibition of hepatic cholesterol synthesis. Oats are
also a rich source of phenolic acids, which are predominantly bound to cell wall
polysaccharides through ester bonds. This bound state within oats means that
phenolic acid bioavailability will largely be determined by interactions with the
colonic microbiota in the large intestine. However, results from in vitro, animal
and human studies have been inconsistent in relation to the impact of oats on the
gut microbiota, possibly due to differences in experimental techniques and
because compounds in oats, other than b-glucans, have not been considered. This
review focuses on the interaction of oat b-glucans and phenolic acids with gut
microbiota, and the subsequent link to cardiovascular health.
Keywords: cardiovascular disease, gut health, gut microbiota, oat, phenolic acids,
b-glucans
Introduction
A high intake of wholegrains is related to improved gut
health (Cooper et al. 2015) and reduced risk of cardio-
vascular disease (CVD) (Thies et al. 2014b; Aune et al.
2016). The health benefits of wholegrains might be due
to effects on inflammation (Nilsson et al. 2008a; Singh
et al. 2013), fasting blood glucose (Pick et al. 1996;
Jensen et al. 2006) and markers of lipid metabolism
(Pins et al. 2002; Behall et al. 2004; Jonnalagadda et al.
2011; Johansson-Persson et al. 2014; Tang et al. 2015;
Aune et al. 2016). A recent meta-analysis of observa-
tional studies indicates that diets rich in wholegrains
are associated with a 21% reduction [relative risk
(RR) = 0.79 (95% CI: 0.74, 0.85)] in CVD risk
(Ye et al. 2012). However, the median daily whole-
grain intake in the UK, estimated from secondary
analysis of data from the National Diet and Nutrition
Survey Rolling Programme 2008/2009–2010/2011, is
20 g/day for adults and 13 g/day for children, which
is higher than in 2000/2001 but remains low and well
below the US wholegrain recommendation of 48 g/day
(no UK wholegrain dietary reference value exist)
(Mann et al. 2015).
It has been suggested that the cardiovascular protec-
tive effects of wholegrain oats are mainly due to their
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dietary fibre content, in particular, soluble oat b-glu-
cans, with established blood cholesterol- and glucose-
lowering properties (Tappy et al. 1996; Tosh 2013;
Whitehead et al. 2014; Tosh & Chu 2015). However,
oats are also a rich dietary source of phenolic acids and
avenanthramides (a class unique to oats) and several
randomised, controlled, crossover studies have sug-
gested that a range of phenolic compounds may be
responsible for some of oat’s health effects (Lamport
et al. 2017; Lockyer et al. 2017; Mills et al. 2017).
However, the phenolic acids in oats are linked to cell
wall polysaccharides by ester linkages and this means
their absorption will be limited until they reach the
large intestine where they may undergo extensive bio-
conversion by colonic microbiota to yield various bioac-
tive metabolites that express local intestinal effects in
the gut, and also systemic effects following absorption
(Vitaglione et al. 2008; Williamson & Clifford 2017).
Previous data have suggested that, in addition to fibre
and non-digestible carbohydrates, phenolics may bene-
ficially modulate the gut microbiota composition and
activity (Connolly et al. 2012b, 2016), which may play
role in the prevention of chronic diseases (He & Shi
2017). For example, the secreting metabolites, such as
secondary bile acids (BAs), short-chain fatty acids
(SCFAs) and trimethylamine-N-oxide (TMAO), act as
hormone-like factors and are sensed by dedicated recep-
tor systems in the human host to play a role in the
pathogenesis of CVD (Brown & Hazen 2015). In this
review, we provide a concise introduction into human
gut health and the contribution that the microbiota play
in influencing markers of CVD pathophysiology, before
outlining the cardiovascular benefits of oat intake and
how these are mediated, in part, by the gut microbiome.
Gut health and the host gut microbiota
The human gastrointestinal tract is a diverse and
dynamic microbial ecosystem, comprising approxi-
mately 1014 bacterial cells and up to 1000 different
species (Thursby & Juge 2017). Firmicutes and Bac-
teroidetes are the two dominant phyla, representing
more than 90% of all the phylotypes, followed by lower
relative abundances of Actinobacteria, Proteobacteria,
Fusobacteria and Verrucomicrobia (Robles Alonso &
Guarner 2013; Power et al. 2014; Zhang et al. 2015).
Commonly considered as the most beneficial bacterial
genera are bifidobacteria, lactobacilli and butyrate pro-
ducers, such as Eubacterium rectale, Roseburia species
(Robles Alonso & Guarner 2013). An appropriate bal-
ance between harmful and health-promoting gut micro-
biota can support human health by: (1) maintaining
host immune homeostasis; (2) increasing the efficiency
of energy production in the gut through fermentation of
non-digestible dietary compounds; (3) synthesising vita-
mins, such as B12 and K; (4) controlling intestinal
epithelial cell proliferation (Clarke et al. 2014);
(5) stimulating immunological defence; (6) creating a
protective barrier; and (7) inhibiting the growth of
potential pathogens (Gibson & Roberfroid 1995; Gib-
son 1998; Gong & Yang 2012; Ahmed Nasef et al.
2014; D’Argenio & Salvatore 2015; Okumura &
Takeda 2017).
Conversely, an unfavourable gut microbiota compo-
sition and function (i.e. dysbiosis) can trigger the
development of diseases through intestinal-derived
endogenous endotoxins, such as lipopolysaccharides,
indoxyl sulphate and L-carnitine (Prakash et al. 2011).
These metabolites may potentiate the development of
acute diseases, such as diarrhoea and chronic diseases,
including obesity, metabolic diseases, cancer and CVD
(Tang & Hazen 2014; Tuohy et al. 2014; Dao et al.
2015). There has been a long understanding of the
interaction between environmental factors and gut
microbiota, including that of pH, peristalsis, redox
potential and nutrient availability (Nicholson et al.
2012). Dietary changes are thought to be responsible
for around 57% of the variation in the gut microbiota,
compared with only 12% for genetics (Brown et al.
2012). For example, a study showed that the microbiota
of mice fed a low-fat, polysaccharide-rich diet markedly
increased in populations of Firmicutes, and decreased in
levels of Clostridium, Eubacterium, Enterococcus and
Bacteroides spp when the mice were switched to a high-
sugar/high-fat diet (Turnbaugh et al. 2009; Nguyen
et al. 2015). On the other hand, a high-fibre diet can
limit the growth of potentially pathogenic E. coli.
(Zimmer et al. 2012), which has been observed in
humans within 24 hours following a change from a
high-fat/low-fibre diet to one which is low-fat/high-fibre
(Wu et al. 2011).
The role of the gut microbiota in the
pathophysiology of cardiovascular disease
Prebiotic effects
Shifts in the gut microbiota composition have been
associated with a wide variety of diseases, including
CVD (Garcia-Mantrana et al. 2018). The promotion of
the growth of specific beneficial gut microbiota is
believed to have preventative effects on CVD due to
the influence of these bacteria on human physiology/
metabolism, including the ability to reduce total serum
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cholesterol, low-density lipoprotein (LDL) cholesterol
and inflammation (Sun & Buys 2015; Ejtahed et al.
2011). Dietary substrates which induce changes in the
growth of favourable bacteria are referred to as ‘prebi-
otics’, which pass largely unmetabolised in the upper
gastrointestinal tract and are selectively utilised by host
microorganisms conferring a health benefit (Gibson
et al. 2017). Established prebiotics are carbohydrate-
based but other substances, such as polyphenols
(Tzounis et al. 2011; Queipo-Ortu~no et al. 2012) and
polyunsaturated fatty acids (Kankaanpaa et al. 2001;
Peluso et al. 2014), might also fit the updated definition
as they can affect the gut microbiome, although more
studies are needed to show subsequent health effects.
Prebiotics may reduce risk factors of CVD through the
stimulation of growth of Bifidobacterium and Lacto-
bacillus, and the subsequent production of SCFAs
(LeBlanc et al. 2017), or possibly through the reduction
in plasma cholesterol (Hooper et al. 2002) and/or fast-
ing plasma glucose and insulin (Ooi & Liong 2010;
Saini et al. 2010; Ruan et al. 2015). Furthermore, con-
sumption of prebiotics has been linked to improved
intestinal function, such as reduced gastrointestinal
inflammation (Laparra & Sanz 2010; Vieira et al.
2013) and mineral absorption, and modulation
of energy metabolism, satiety and immune function
(Gibson & Roberfroid 1995; Gibson 1998; Pereira &
Gibson 2002; Nicholson et al. 2012).
Structural effects
The large gut’s enormous surface area helps to absorb
nutrients, water and electrolytes from food but at the
same time, it needs to provide a tight barrier against
harmful substances and pathogens. One way in which
the gut microbiota may confer health effects is via
their potential to maintain large gut integrity (Konig
et al. 2016). Gut hyperpermeability (leaky gut) results
from structural changes induced by Gram-negative
bacteria, which allows bacterial cell wall products,
such as lipopolysaccharide and peptidoglycans, to
enter into the bloodstream and activate macrophages.
Also, gut microbiota-derived lipopolysaccharide can
induce foam cell formation, and this can reduce
reverse cholesterol transport and increase insulin resis-
tance, hyperlipidaemia, vascular inflammation (Aki
et al. 2008) and thus increase CVD risk.
Bile acid synthesis/clearance/metabolism
BAs have indirect (through cholesterol metabolic path-
ways) and direct effects (through interaction with
myocytes) on blood cholesterol levels, atherosclerotic
plaque formation and myocardial function and thus are
hypothesised to reduce CVD risk (Khurana et al.
2011). Figure 1 illustrates the pathways of BA synthesis
and cholesterol biotransformation in the liver (Ridlon
et al. 2006). Primary BAs are further metabolised via
conjugation to glycine or taurine in the liver, synthe-
sised to bile salts and transported to the gallbladder.
Following a meal and the release of cholecystokinin
from the duodenum, the gallbladder contracts resulting
in bile salts flowing into the duodenum, which in turn
promotes the absorption of dietary lipids (Wahlstrom
et al. 2016). The bacteria in the lower intestine are cap-
able of converting primary BAs, by deconjugation and
hydroxyl group oxidation at C-3, C-7, and C-12, and
7a/b-dehydroxylation, to secondary BAs, which pre-
dominate in human faeces (Sagar et al. 2015; Wahl-
strom et al. 2016). Even though some are lost in faeces,
most BAs are absorbed in the ileum and return to the
liver where they are deconjugated and released into the
small intestine (Ridlon et al. 2006). The genera of the
gut microbiota involved in BA metabolism are Bac-
teroides, Bifidobacterium, Clostridium, Lactobacillus
and Eubacterium (Gerard 2014). BA metabolites result-
ing from microbial transformation may act as signalling
molecules and regulate cardiovascular function through
the TGR5 (G-coupled protein receptor) and FXR (far-
nesoid x receptor), thus potentially inhibiting inflamma-
tion and maintaining epithelial cell integrity (Miyazaki-
Anzai et al. 2014), and modifying vascular tone (Nie
et al. 2015; Wahlstrom et al. 2016). Furthermore, Bac-
teroides fragilis, B. vulgatus, Clostridium perfringens,
Listeria monocytogenes and several species of Lacto-
bacillus and Bifidobacterium interfere with cholesterol
absorption from the gut by deconjugating bile salts, via
bile salt hydrolases (Jones et al. 2008), which means
cholesterol is less easily absorbed and more likely to be
excreted in faeces, resulting in lowered blood choles-
terol (Hofmann 1999; Ridlon et al. 2006; Nicholson
et al. 2012; Tuohy et al. 2014).
Short-chain fatty acids
SCFAs are the major end product of both carbohy-
drate and amino acid bacterial fermentation in the
human large intestine (Morrison & Preston 2016).
The main SCFAs are acetate, propionate and butyrate;
less common are formate, valerate, caproate and
branched-chain fatty acids (Macfarlane & Macfarlane
2003; Nicholson et al. 2012). Butyrate can be metabo-
lised by colonocytes or absorbed and metabolised
further in the liver, where they are metabolised
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(Rıos-Covian et al. 2016). SCFAs can act as an energy
source for gut epithelial cells, improve intestinal
defence against pathogens, modulate inflammation
and possibly influence satiety (Russell et al. 2013).
Butyrate may play a key role in regulating gene
expression, inflammation and maintaining homeostasis
of colonic mucosa through stimulating the production
and release of the gut hormone glucagon-like peptide-
2 (GLP-2) in enteroendocrine L cells (Tappenden et al.
2003; Hamer et al. 2008; Louis & Flint 2009). In
addition, SCFAs decrease systemic levels of blood
lipids by inhibiting hepatic cholesterol synthesis and/or
redistributing cholesterol from plasma to the liver
(Pereira & Gibson 2002). SCFAs are also thought to
bind to specific G protein-coupled receptors, leading
to the favourable regulation of lipid and glucose meta-
bolism in the context of CVD (den Besten et al. 2013;
Canfora et al. 2015; Kasubuchi et al. 2015). Another
gut microbiota metabolism-dependent effect is the
microbial conversion of choline and L-carnitine to
trimethylamine (TMA) to TMAO. TMAO is thought
to increase atherosclerotic CVD by altering cholesterol
transport, potentially increasing macrophage activa-
tion (Randrianarisoa et al. 2016).
Oat components
Oats (Avena sativa) are unique among cereals due to
their multifunctional characteristics and nutritional
profile (Table 1). They supply protein, carbohydrate
(primarily starch), crude fat, dietary fibre, unique
antioxidants and vitamins and minerals (Welch 1994;
Sadiq Butt et al. 2008; Menon et al. 2016). Oats have
been grown for thousands of years, mainly as an ani-
mal feed crop, but during the 19th century, oats
gained recognition as a ‘healthy’ food (Menon et al.
2016). Numerous reviews suggest that diets rich in
oats may reduce inflammatory bowel disease and coe-
liac disease (Haboubi et al. 2006; Thies et al. 2014),
attenuate CVD progression (Ruxton & Derbyshire
2008; Thies et al. 2014), and regulate glucose control
in type 2 diabetes (Connolly et al. 2012b; Hou et al.
2015).
The nutrient profile and quality of oats depend on
several factors, such as growth environment, genotype
and the interaction between environment and geno-
type (Peterson et al. 2005). The main constituent
(60%) of oat grains is starch (rapidly digestible,
slowly digestible and resistant), located in the
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Figure 1 Bile acid biosynthesis. Primary bile acid synthesis in the liver: cholesterol is synthesised to cholic acid (CA) and chenodeoxycholic acid (CDCA) by
the cholesterol 7 alpha-hydroxylase (CYP7A1) enzyme. In the intestinum, the bacterial 7 alpha-dehydroxylase converts the CA and CDCA to deoxycholic acid
(CDA) and lithocholic acid (LCA), respectively. The bile acid receptors FXR farnesoid x receptor (FXR) and G protein-coupled bile acid receptor (TGR5) regu-
late bile acid synthesis, glucose homeostasis and lipid metabolism. [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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endosperm. Resistant starch is recognised as a fer-
mentable fibre source for gut microbiota, which results
in the production of SCFAs in the colon (Ovando-
Martınez et al. 2013; Gangopadhyay et al. 2015;
Rasane et al. 2015). Moreover, oats are a source of
high-quality protein, lipids (especially unsaturated
fatty acid such as oleic, linoleic and palmitic acid),
traces of minerals (mainly calcium and iron), B and E
vitamins and phenolic compounds (Gangopadhyay
et al. 2015; Rasane et al. 2015; Menon et al. 2016).
Oat phytochemicals
Dietary phenolics, such as hydroxycinnamic, hydroxy-
benzoic acids and avenanthramides, are natural phe-
nolic components in oats (Shewry et al. 2008). They
are found in three different forms within the oat food
matrix: as soluble free acids; as soluble conjugates
esterified to low molecular weight components such as
sugars; and as insoluble bound acids esterified to high
molecular weight components, including lignin, cell
wall polysaccharides such as arabinoxylan (Stevenson
et al. 2012) and storage proteins in the aleurone layer
and the pericarp (Shewry et al. 2008). The main
hydroxycinnamic acids present in oats include ferulic
acid, caffeic, p-coumaric (Fig. 2), o-coumaric and sina-
pic acids. Hydroxybenzoic acid derivatives are proto-
catechuic, syringic, vanillic, p-hydroxybenzoic and
gallic acids (Kern et al. 2003; El-Seedi et al. 2012;
Kumar & Pruthi 2014; Yang et al. 2014).
Hydroxycinnamic acids all have a C6C3 carbon
skeleton with a double bond in the side chain that
may have a cis or trans configuration. By far the most
abundant hydroxycinnamic in oats is the trans-ferulic
acid, with contents ranging from 95 to 386 lg/g
(Shewry et al. 2008). Analytical data indicate that, on
average, 19% of these phenolic acids (range: 50–110
lg/g) are present in the soluble state, 34% as conju-
gates (range: 111–314 lg/g) and 47% bound (range:
131–640 lg/g) (Shewry et al. 2008). Another phenolic
group specific to oats are the avenanthramides (AVA)
(Fig. 3), consisting of an amide conjugate of anthrani-
lic acid and hydroxycinnamic acids. The three major
subgroups are avenanthramide-A (AVA-A), avenan-
thramide-B (AVA-B) and avenanthramide-C (AVA-C),
which occur in the bran or outer layers of the kernel
(Manach et al. 2004). Total contents of avenan-
thramides in oats range from 42 to 91 lg/g (Emmons
& Peterson 1999; Liu et al. 2004; Manach et al.
2004; Chen et al. 2007).
Fibre
Wholegrain oats are typically 10%–12% fibre, of
which roughly 40% is soluble and 60% insoluble (cel-
lulose) (Menon et al. 2016). Mixed-linkage (1-3)(1-4)-
b-D-glucans (b-glucans) (82% water-soluble fraction)
together with arabinoxylans are important sources of
soluble as well as insoluble dietary fibre (Shewry et al.
2008; El Khoury et al. 2012). The soluble b-glucans
located throughout the subaleurone cell walls are one
of the most commonly studied components of oats
(Kim et al. 2006; Cloetens et al. 2012; Rebello et al.
2014; Zhang et al. 2016). A 100 g of oats contains
3–6 g b-glucans (Shewry et al. 2008).
Bioavailability of phytochemicals and physiological
effects of b-glucans
It has been estimated that only 5%–10% of dietary
polyphenols are absorbed in the small intestine, with
the remaining fraction reaching the large intestine
where they are metabolised by the gut microbial com-
munity (Manach et al. 2005; Cardona et al. 2013).
Table 1 Nutritional composition of raw oat bran. Data from the
US Department of Agriculture National Nutrient Database (USDA
2015)
Nutrient Value per 100 g
Energy (kcal) 246
Protein (g) 17.30
Total fat (g) 7.03
Fatty acids, total saturated (g) 1.6
Fatty acids, total monounsaturated (g) 2.38
Fatty acids, total polyunsaturated (g) 2.77
Total carbohydrate (g) 66.22
Sugar (g) 1.45
b-glucans (g)* 4.5–5.6
Arabinoxylans (g)* 3.83–13.20
Non-starch polysaccharide (g) 7.1
Calcium (mg) 58
Iron (mg) 5.41
Potassium (mg) 566
Sodium (mg)* 4
Magnesium (mg) 235
Zinc (mg) 3.11
Thiamine (mg) 1.17
Riboﬂavin (mg) 0.22
Niacin (mg) 0.93
Vitamin B (mg) 0.16
Folate (lg) 52
Vitamin E (mg) 1.01
Vitamin K (lg) 3.2
Total phenolic (mg)* 35.1–87.4
*Data from Shewry et al. (2008).
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The absorption and metabolism of ferulic acid can be
affected by the form of food matrix ingested (Kern
et al. 2003; Rein et al. 2013). Counterintuitively,
fibre-bound ferulic acid in wheat bran has been
observed to be more bioavailable than free ferulic acid
(Rondini et al. 2004). The differences observed in
their absorption may relate to the rapid cleavage of
the fibre–phenolic ester bond by the intestinal micro-
biota, which generates a higher amount of free pheno-
lic acids in the large gut, increases their time in the
plasma and decreases the level of urinary excretion
(Chesson et al. 1999; Rondini et al. 2004). Our group
reported intake of 60 g oat bran (2.5 mg avenan-
thramides, 28.6 mg phenolic acids) resulted in elevated
urinary excretion of 30 phenolic acids metabolites,
amounting to total recovery of 22.9%  5.0%,
mainly between 0–2 and 4–8 hours (Schar et al.
2017). The predominant metabolites included vanillic
acid, 4- and 3-hydroxyhippuric acids and sulphate
conjugates of benzoic and ferulic acid (accounting for
two-thirds of total phenolic excretion). The results
suggest that bound phenolic acids present in oats are
rapidly released by the microbiota. Similarly, another
human study (Zhang et al. 2017) showed peak plasma
concentrations of avenanthramides between 2 and 3
hours after high (229.6 mg/kg) AVA intake and 1 and
2 hours for low AVA intake (32.7 mg kg). AVA-B
demonstrated a longer half-life and a slower elimina-
tion rate than AVA-A and AVA-C. The bioactive
properties of polyphenols are greatly dependent on
their bioavailability (Chen et al. 2004; Kroon et al.
2004; Manach et al. 2004; Chen et al. 2007). These
polyphenols have been observed to inhibit vascular
smooth muscle cell proliferation and enhance nitric
oxide production (Nie et al. 2006).
The physiological activity of b-glucans is in part
related to their effects on bile reabsorption and
through their ability to increase intestinal chyme vis-
cosity, effects that are dependent on both the concen-
tration and molecular weight of the b-glucans
consumed (Shewry et al. 2008; Menon et al. 2016).
The molecular weight of b-glucans varies between 100
000 and 1 200 000 g/mol, and those of a small molec-
ular size (370 000 g/mol) have been reported to be less
effective at reducing cholesterol levels (Kim et al.
2006) compared with those of high molecular weight
Figure 2 Chemical structure of the main hydroxycinnamates in oats.
Figure 3 Chemical structure of the avenanthramide in oats. Avenanthramide-A (AVA), avenanthramide-B (AVB) and avenanthramide-C (AVC).
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(Braaten et al. 1994). The solubility of b-glucans is
another important factor influencing their physiologi-
cal activity (El Khoury et al. 2012). Their ability to
form highly viscous small intestinal chyme likely con-
tributes to the health benefits of b-glucans, as it has
been reported that there is an inverse linear relation-
ship between measures of postprandial blood glucose
and insulin responses (to an oral glucose load) and the
viscosity of the chyme (Wood et al. 2000; Chen &
Raymond 2008; Wolever et al. 2018).
Cardiovascular benefits of the oat intake
Atherosclerosis is one of the main underlying patho-
physiological processes in CVD development (Stamler
et al. 1986; Shepherd et al. 1995), with several differ-
ent actions, such as oxidation of LDL cholesterol,
adhesion of monocytes across the endothelial surface,
development of monocytes to macrophages and the
formation foam cells (Andersson & Hellstrand 2012).
The potential modulation of atherogenic pathways
following oat intake has been suggested and may
involve anti-inflammatory activity, the maintenance
of endothelial function and the reduction in plasma
cholesterol (Fig. 4) (Ryan et al. 2007, 2011;
Jonnalagadda et al. 2011; Thies et al. 2014; White-
head et al. 2014; Shen et al. 2016). Additionally, oat
fibre and phenolics are capable of interacting directly
with the gut microbiota, leading to a shift in their pro-
file and composition, secondary changes in cholesterol
and bile metabolism, and the production of key
metabolites such as SCFAs and phenolic acids metabo-
lites (Fig. 4).
Effects of oat intake on microbiome composition –
in vitro and animal data
Several in vitro fermentation (Table 2) and animal
studies (Table 3) suggest that increased oat intake
leads to gut microbiota alterations. In vitro fermenta-
tion of oat grains has been shown to increase Bifi-
dobacterium and Lactobacillus populations (Connolly
et al. 2010) and Bacteroides and Prevotella groups
(Chappell et al. 2015), whilst decreasing clostridia
levels (Kedia et al. 2009). However, although oat-
derived b-glucans extracts increased Lactobacillus–
Enterococcus after 5 hours and Bacteroides after 24
hours in one in vitro study, they were found to not
influence bifidobacterial growth (Hughes et al. 2008).
In another in vitro study, it has been reported that the
Inhibit CYP7A1 
Insulin sensitivity 
Lipid accumulation 
Oat intake
Gel formatting in the intestine,
Deconjugating bile salt 
Lipid absorption
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Adipogenesis
Inflammation 
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Figure 4 Potential mechanisms in the digestion system of the cardiovascular beneﬁts of oats. Oats may interact directly with the gut microbiota leading to a
shift in their proﬁle and composition, changes in cholesterol and bile metabolism, and the production of key metabolites such as short-chain fatty acids.
Abbreviations: SCFAs (short-chain fatty acids), GPR41 and GPR43 (G protein-coupled receptor), PYY (peptide YY), GLP1 (glucagon-like peptide 1) and
CYP7A1 (cholesterol 7 alpha-hydroxylase). [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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b-glucans are fermented by Bacteroides spp but not by
Lactobacillus and Bifidobacterium (Crittenden et al.
2002). The fermentation of oats in anaerobic, pH-con-
trolled, faecal batch cultures has been shown to
increase SCFA production, with significant increases in
acetate, propionate and butyrate levels (Hughes et al.
2008; Kedia et al. 2009; Kim & White 2009; Con-
nolly et al. 2010, 2012b).
Consumption of oats by rodents has been reported
to result in many specific changes in their micro-
biota, such as increases in the growth of Prevotel-
laceae, Lactobacillaceae and Alcaligenaceae families
175.5% (P = 0.03), 184.5% (P = 0.01) and 150.0%
(P = 0.004). However, these results are not consistent
with the findings from other animal studies that indi-
cate oat bran intake increases only Bifidobacterium
and Lactobacillus growth (Drzikova et al. 2005;
Berger et al. 2014). The range of oat products used
in these studies, including oat flour and bran
(Drzikova et al. 2005), or insoluble fibre and soluble
fibre combinations (Zhou et al. 2015), might explain
the reported variability in microbiota growth in
rodents. Hence, further well-designed in vitro and
human studies are required to examine which oat
components may result in beneficial changes to the
microbiota.
Overall, these studies indicate inconsistent findings
regarding the influence of oats on the growth of the
microbiota and their diversity, which might be partly
explained by the various different study and experi-
mental designs. It is also important to note that these
studies considered only the influence of the b-glucans
fraction within oats and not other oat bioactives, such
as polyphenols, which have also been observed to
Table 2 The impact of oats on the gut microbiota and short-chain fatty acid (SCFA) production based on data from in vitro studies at
24 hours
Reference Intervention Effects on bacterial composition Effects on SCFA production
Hughes et al. (2008) Oat-derived b-glucans
Low molecular
weight (LMW) 150 kDa
High molecular
weight (HMW) 230kDa
Atopobium ↑ - LMW and HMV
Bacteroides – Prevotella ↑ - LMV
Lactobacillus/Enterococcus ↓ - LMV and HMV
Clostridium histolyticum ↑ - LMV and HMV
Acetate ↑ -
LMV, HMV
Propionate ↑ -
LMV, HMV
Kedia et al. (2009) Oat bran fraction (OB)
Whole oat ﬂour (WOF)
Biﬁdobacterium ↑ - OB and WFO
Lactobacillus/Enterococcus ↑ - OB
Clostridium ↓ - 24 hours, OB
Clostridium ↑ - 24 hours, WOF
Acetate, butyrate, propionate ↑ -
OB, WOF
Kim and White (2009) Oat-derived b-glucans
Low b-glucans
(LB) – 5.31% b-glucans
High b-glucans
(HB) – 7.70% b-glucans
No data Acetate, butyrate, propionate ↑ -
LB, HB
No signiﬁcant
differences between LB vs. HB
Connolly et al. (2010) Oat grain ﬂakes
0.53–0.63 mm (size 23)
0.85–1.0 mm (size 25–26)
Biﬁdobacterium genus ↑ - size 25–26
Eubacterium ↑ - sizes 23 and 25–26
Acetate ↑ -
size 23
Acetate, propionate, butyrate ↑ -
size 25–26
Connolly et al. (2012b) Wholegrain oat-based cereals
• Jumbo porridge oat (JPO)
• 100% wholegrain
aggregate (WGA)
• Granola (G)
• 70% wholegrain loops (WGL)
• Instant porridge (IP)
JPO, IP, G, WGA Biﬁdobacterium ↑
JPO, G – Atopobium ↑
G, WGA, IP, WGL
- Bacteroides, Prevotella ↑
G, WGA, WGL - Lactobacillus/Enterococcus ↑
P, WGA – Clostridium ↓
Acetate, propionate ↑ -
JPO, IP, WGA, WGL, IP
Butyrate ↑ -
IP, WGA
Connolly et al. (2012a) Toasted (T), partially toasted (PT) and
raw (R) wholegrain wheat ﬂakes
Biﬁdobacterium genus ↑ -
T, PT and R
C. hystolyticum subgroup, Lactobacillus ↑ - R
Acetate, propionate ↑ - T, PT R
Chappell et al. (2015) Belinda oats Bacteroides ↑
Firmicutes ↓
Acetate, propionate, butyrate ↑
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interact with the gut microbiota (van Duynhoven et al.
2011; Cardona et al. 2013; Kay 2015).
Effects of oat intake on microbiome composition –
human trials
Whilst in vitro (Kedia et al. 2009; Connolly et al.
2010, 2012a) and animal studies (Immerstrand et al.
2010; Berger et al. 2014) indicate that oat intake
increases the production of SCFAs, these effects are
difficult to quantify in humans as SFCAs are rapidly
absorbed or utilised in the large intestine. For exam-
ple, butyrate is almost entirely used by the colonocytes
as their preferred energy substrate (Cummings et al.
1987), propionate is primarily absorbed and removed
by the liver (Hong et al. 2005), whilst acetate passes
into the peripheral circulation (Roediger 1980). The
use of in vitro tools can help to investigate whether
various substrates lead to increased SCFA generation,
as faecal SCFA measurements are an uncertain esti-
mate of colonic SCFA production (Valeur et al. 2016).
Findings from human trials on the effects of oats on
the microbiota vary, possibly due to differences in
study design (i.e. intervention dose, study duration,
study population, the method of microbial enumera-
tion) and because these studies assessed the effects of
fibre but not the polyphenols in oats (Table 4). Two
randomised controlled trials provide evidence that
wholegrain wheat may exert effects on gut microbiota
(Costabile et al. 2008; Vitaglione et al. 2015). A daily
intake of 48 g of wholegrain wheat significantly
increased the growth of Bifidobacterium (0.8 log10
cells per g faeces) and Lactobacillus (0.6 log10 cells
per g faeces) and increased plasma ferulic acid levels
(Costabile et al. 2008). In contrast, intake of 70 g per
day of wholegrain wheat was found not to increase
levels of Bifidobacterium, although faecal ferulic acid
levels were found to be associated with an increase in
Bacteroides, Firmicutes and a reduction in Clostridium
(Vitaglione et al. 2015). To date, no human trials have
studied the direct effects of extracted or purified oat
phenolic acids on the growth of the microbiota, or
whether they contribute to the prebiotic effects of
wholegrain intake, although data do exist on the
impact of flavanols, which have been found to
promote the growth of specific beneficial bacteria
(Tzounis et al. 2011). These data suggest that phenolic
acids present in wholegrain cereals may potentiate gut
microbiota diversity; however, further research is
required to distinguish between the effects of fibre and
polyphenols on gut health.
Impact of oat intake on cholesterol metabolism and
bile acid synthesis
Oat b-glucans have been suggested to lower choles-
terol by causing an increased viscosity of the intestinal
chime (Ryan et al. 2007). The gel formed is thought
to act as a physical barrier to lipid (triglycerides)
absorption in the small intestine, in particular that of
cholesterol reabsorption (Bae et al. 2010; Andersson
& Hellstrand 2012; Bao et al. 2014). b-glucans have
also been shown to bind to luminal BAs, which
increases the excretion of bile in the faeces and trig-
gers an increase in hepatic conversion of cholesterol
into BAs, thereby decreasing blood cholesterol levels
(Lia et al. 1995; Bae et al. 2010; Grundy et al. 2017).
It has been reported that the intake of 75 g of
Table 3 Animal studies examining the effects of oat intake on growth of gut microbiota and short-chain fatty acid (SCFA) production
Reference Intervention (duration)
Oat effects on bacterial composition
and/or SCFA production compared to control Animals
Drzikova et al. (2005) Oat ﬂour (F); oat bran (B); oat ﬂour (F)
(autoclaved)
(6 weeks)
Biﬁdobacterium genus ↑ - F, B
Bacteroides ↑ - F
Rats
Immerstrand et al. (2010) Oat bran (OB; b-glucans – 1800 kDa or 2348 kDa)
Processed oat bran (POB; b-glucans – 1311 kDa,
241 kDa, 56 kDa, 21 kDa, 10 kDa)
(4 weeks)
Acetate, propionate, butyrate ↑ -
OB, POB
Mice
Berger et al. (2014) High fat diet – barley husks, rye bran,
ﬁbre residue from oat milk
(4 weeks)
Lactobacillus ↑
propionate, butyrate ↑
Mice
Zhou et al. (2015) Wholegrain oat ﬂour (WGO),
Low bran oat ﬂour (LBO)
(8 weeks)
Prevotellaceae, Lactobacillaceae, and
Alcaligenaceae families relative
abundance – ↑ - WBO
Clostridiaceae, Lachnospiraceae families – ↑ - LBO
Mice
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extruded oat bran (11 g b-glucans) resulted in a near
doubling of serum 7 alpha-hydroxy-4-cholesten-3-one
concentration within 8 hours, which lead to increased
BA synthesis (Andersson et al. 2002). BA excretion is
well known to stimulate cholesterol uptake from the
circulation, resulting in a decreased serum cholesterol
concentration (Grundy et al. 2017).
Oat intake and short-chain fatty acid production
SCFA production is highly dependent on the donor
and availability of substrates (Cook & Sellin 1998).
The ability of oats (and isolated b-glucans) to increase
SCFA production is well established (Connolly et al.
2010, 2012a; Berger et al. 2014). After 12 hours of
in vitro fermentation, oat bran (containing 22% oat
b-glucan) induced significantly higher concentrations
of propionate compared to other prebiotic dietary
fibres, such as inulin and xylooligosaccharide (Carlson
et al. 2017). The production of SCFAs in the large
intestine following oat consumption has been reported
and postulated to contribute to reductions in serum
lipids and other CVD risk markers (Andersson &
Hellstrand 2012). As such, SCFAs may act as media-
tors of the beneficial effects of wholegrain oat intake
of human CVD. These effects might be dependent on
SCFAs’ ability to: (1) affect liver and muscle cellular
metabolism via their potential to increase insulin sensi-
tivity and decrease lipid accumulation in liver (Oda
et al. 1994; Ulmius et al. 2011; Zhang et al. 2012;
Chang et al. 2013; McNabney & Henagan 2017);
(2) suppress cholesterol synthesis, increase fatty acid
Table 4 The relationship between oats, the growth of gut microbiota and short-chain fatty acid (SCFA) production based on data from
human intervention trials
Reference Intervention (duration)
Oat effects on bacterial composition and/or
SCFA production compared to control
Bridges et al. (1992) 20 (38–73 years) hypercholesterolaemic men
Oat bran – 34 g/day total ﬁbre and 13.4 g/day soluble ﬁbre
Control – 14 g/day total ﬁbre and 3 g/day soluble ﬁbre
(3 weeks)
SCFA in peripheral serum
Serum acetic acid ↑
Martensson
et al. (2005)
56 adults
(20–70 years, 24 men/32 women)
with moderately increased plasma cholesterol levels
Fermented oat-based products (FO) (3–3.5 g/day – b-glucans)
Fermented ropy, oat products (FRO)
Fermented dairy-based product (control)
(Control – 3 weeks, treatment – 5 weeks)
Total bacteria count ↑
Biﬁdobacterium ↑ - FO, FRO
Nilsson et al. (2008b) 25 healthy adults
(20–47 years, 10 men/15 women)
40 g b-glucans enriched oat bran
(40 g oat bran, 20 g dietary ﬁbre, 10 g
glucan in four slices of bread)
Control – baseline samples, week 0
(12 weeks)
SCFAs in faeces
Acetic, propionic, butyric, isobutyric, isovaleric - ↑
Valeur et al. (2016) 10 healthy adults
(22–49 years, 2 men/8 women)
60 g oatmeal porridge
(8.5 g ﬁbre, 4.7 g glucans)
Control – baseline samples, day 1
(1 week)
Intestinal gas production SCFAs and no changes – faeces
b-galactosidase and urease - ↓
Rectal level of PGE2 – no signiﬁcant difference
Connolly et al. (2016) 32 mild or hypercholesterolaemia adults
(23–64 years, 12 men/20 women)
Wholegrain oat granola (WGO) - 45 g
granola breakfast cereals
(6.3 g ﬁbre, 2.9 g glucans)
Non-wholegrain (NWG) – 45 g
non-wholegrain breakfast cereals (control)
(3 g ﬁbre, no glucans)
(6 weeks)
SCFAs no signiﬁcance differences
Total bacteria count ↑
Biﬁdobacterium ↑
Lactobacilli ↑
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oxidation and decrease de novo fatty acid synthesis in
the liver (Andersson et al. 2002, 2017; Cloetens et al.
2012; Han et al. 2015); (3) increase adipogenesis and
decrease lipolysis (Gao et al. 2015; Heimann et al.
2016); (4) modulate satiety through their potential to
bind to G protein-coupled receptors (GPR41, GPR43),
leading to the increased production of the gut hor-
mones glucagon-like peptide-1 and peptide YY
(Hooda et al. 2010; Koh et al. 2016; Rebello et al.
2016) and regulate satiety centrally (Bridges et al.
1992; Canfora et al. 2015; Canfora & Blaak 2017);
and 5) improve colon and liver glucose homeostasis
via their induction of intestinal gluconeogenesis (den
Besten et al. 2013; Bourassa et al. 2016; Cheng et al.
2017; Jayachandran et al. 2018) (Fig. 4). In addition,
butyric acid has been reported to increase phenolic
acid absorption in the colon (Ziegler et al. 2016),
which subsequently may induce endothelium-depen-
dent vasodilation (Suzuki et al. 2002, 2007; Choi
et al. 2012). Recent studies have also indicated that
the ratio of acetate and propionate may be important
for defining the precise effects of SCFAs on various
physiological systems. For example, a high serum acet-
ate:propionate ratio has been associated with reduc-
tions in total serum cholesterol in men (Weitkunat
et al. 2017; Boets et al. 2017; Wolever et al. 1996).
Conclusions
Evidence suggests that wholegrain oats may reduce
CVD risk due to their influence on lipid metabolism
and plasma cholesterol levels. Oat b-glucans are likely
to be partly responsible for any effects as they can
change the gut microbiota composition, increase
cholesterol excretion in the gut and increase the levels
of SCFAs, which may inhibit hepatic cholesterol syn-
thesis and affect glucose homeostasis in adipose tissues
and muscle cells. However, inconsistent findings from
in vitro, animal and human studies have been reported
regarding the influence of oat intake on these out-
comes, possibly due to differences in experimental
techniques and the focus on b-glucan rather than other
compounds present in oats, such as phenolic acids and
avenanthramides, which may also contribute to benefi-
cial changes in the gut microbiota and lipid/cholesterol
metabolism. Clinical, observational and experimental
studies to date have not explored the extent to which
cardiovascular benefits are dependent on oat fibre or
phenolic acid levels. Hence, further randomised, con-
trolled trials are required to examine the relative
effects of oat phenolics on microbial pathways and
cardiovascular risk markers.
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